- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05178511
Ensatinib Treat Second-generation ALK-TKI Resistance After Second-generation ALK-TKI Resistance (ERSGATR)
January 4, 2022 updated by: Li Zhang, MD
a Prospective, Open Phase ii Clinical Study in Patients With alK-positive Non-small Cell Lung Cancer Treated With Ensatinib After Second-generation ALK-TKI Resistance
After the use of second-generation ALK-TKI drug resistance, about 50% of tissue biopsies showed mutations in the ALK kinase domain, and appropriate ALK-TKI could be selected according to different mutation sites .Phase I/II clinical trials in the US of ensatinib showed ORR of 25% (4/16) in patients previously treated with crizotinib and second-generation ALK-TKI (N=16) .In the phase II registered clinical study in China, biomarker analysis also showed that the ORR of ensatinib against drug resistance site G1202R was 33% (2/6).The ORR of I1171 and F1174 were 50% (2/4) and 71% (5/7), respectively, suggesting that ensatinib may still be effective in patients with drug resistance to other second-generation ALK inhibitors .
Investigators designed this study to evaluate the clinical efficacy of ensatinib after second-generation ALK-TKI resistance.The study was a single-arm, multi-center Phase II clinical study, using ORR of patients with measurable lesions as the primary endpoint, and using Simon two-stage design to estimate the required sample size.At a 5% level of significance and 85% confidence, a minimum of 40 evaluable subjects were required for both phases.In the first stage, 20 patients were enrolled.
If 2 patients had objective response, an additional 20 patients were enrolled in the second stage.
If more than 5 patients /40 patients had objective response, the therapeutic drugs were considered effective.Eligible patients will take 225mg of ensaritinib orally once daily, on an empty stomach or with food, until the patient develops disease progression, develops unacceptable toxicity, the investigator or subject decides to drop out, loses follow-up, starts another antitumor therapy, or dies.The primary end points were objective response rate (ORR) to disease progression, occurrence of unacceptable toxicity, investigator or subject decision to drop out, loss of follow-up, initiation of other antitumor therapy, or death.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
40
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Wen Feng Feng, Doctor
- Phone Number: 15322302066
- Email: fangwf@sysucc.org.cn
Study Locations
-
-
Guangdong
-
Guangzhou, Guangdong, China, 510060
- Recruiting
- Sun Yat-sen University
-
Contact:
- Fang WenFeng, dooctor
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) confirmed histologically or cytologically ;
- Patients confirmed as ALK positive (FISH or Ventana IHC or RT-PCR, NGS) in previous written reports.Disease progression after continuing treatment with prior second-generation ALK-TKI resistance (allowing crizotinib resistance) (as per RECIST 1.1);
- Maximum one chemotherapy is allowed;The interval between the last administration of second-generation ALK-TKI and the trial enrollment should be at least 7 days;
- Gender: both male and female;Age: ≥18 years old;
- physical status score was 0-2;
- survival ≥3 months;
- certain organ system functions (no blood transfusion or use of constituent blood within 14 days before test);
- Asymptomatic CNS metastases that do not require treatment with steroids or anticonvulsants;If there is CNS metastasis, radiotherapy can be performed first, and no progress can be made after ≥28 days.Meningeal disease was not included in the group;
- Patients must have measurable lesions according to RECIST1.1 criteria;
- Willing and able to follow the trial and follow-up procedures;
- Able to understand the nature of the experiment and sign written informed consent voluntarily.
Exclusion Criteria:
- Patients who had previously only used crizotinib or loratinib;
- Currently receiving other systemic anti-tumor treatments;
- history of malignancy other than lung cancer in the past 3 years (excluding cured basal cell tumor of the skin, early gastrointestinal [GI] tumor resected under endoscope, carcinoma in situ of the cervix);
- Patients who participated in clinical trials of other investigational drugs within weeks prior to initial ensatinib administration;
- Major surgery or immunotherapy within 4 weeks prior to initial; dosing;Radiation therapy was received within 2 weeks prior to initial dosing;
- In the investigator's opinion, may increase the risk associated with study participation or may interfere with the interpretation of study results;
- Other conditions considered unsuitable for participation in the study by the investigator.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: hydrochloric acid ensartinib
Ensatinib 225mg daily, QD, until progression or intolerance
|
Ensaritinib was taken orally once 225mg, on an empty stomach or with food, until the patient developed disease progression, developed unacceptable toxicity, the investigator or subject decided to drop out, lost follow-up, initiated other antitumor therapy, or died
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Objective response rate
Time Frame: 0 up to 8 weeks
|
0 up to 8 weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Progression free survival
Time Frame: 0 up to12 months
|
0 up to12 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
December 1, 2021
Primary Completion (Anticipated)
July 1, 2023
Study Completion (Anticipated)
December 31, 2024
Study Registration Dates
First Submitted
December 2, 2021
First Submitted That Met QC Criteria
January 4, 2022
First Posted (Actual)
January 5, 2022
Study Record Updates
Last Update Posted (Actual)
January 5, 2022
Last Update Submitted That Met QC Criteria
January 4, 2022
Last Verified
January 1, 2022
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- BD-EN-IV001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- ICF
- ANALYTIC_CODE
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on The Diagnosis Was ALK Positive NSCLC
-
Betta Pharmaceuticals Co., Ltd.Unknown
-
Xuanzhu Biopharmaceutical Co., Ltd.Not yet recruiting
-
Sameek RoychowdhuryNational Cancer Institute (NCI)WithdrawnLocally Advanced Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | ALK Gene Mutation | Metastatic Malignant Neoplasm in the Brain | Advanced Malignant Neoplasm | ALK Fusion Protein Expression | Metastatic Malignant Neoplasm in the Central Nervous System | ROS1 Gene Mutation | ALK Gene... and other conditionsUnited States
-
PfizerCompletedALK-positive Non Small Cell Lung Cancer (NSCLC) and ROS1-positive NSCLCUnited States, Canada, Australia, Taiwan, Singapore, Japan, Korea, Republic of, Spain, Belgium, Switzerland, France, Germany, Hong Kong, Italy
-
Cancer Institute and Hospital, Chinese Academy...RecruitingUntreated Advanced NSCLC Patients | FISH Identified ALK Fusion Positive or NegativeChina
-
Peking University Cancer Hospital & InstituteBetta Pharmaceuticals Co., Ltd.RecruitingNSCLC Stage IV | NSCLC Stage IIIB | ALK PositiveChina
-
PfizerTerminatedALK or ROS1-positive NSCLCChina
-
Dr Joanne CHIURecruitingALK Gene Rearrangement Positive | EGF-R Positive Non-Small Cell Lung Cancer | EGFR Activating Mutation | Nsclc | ROS1 Gene Rearrangement | ROS1 Positive NSCLC - Reactive Oxygen Species 1 Positive Non-Small Cell Lung CancerHong Kong
-
Centre Francois BaclesseGFPCRecruitingALK Gene Rearrangement Positive | NSCLC Stage IV | NSCLC Stage IIIB | EGFR Gene Mutation | ROS1 Gene MutationFrance
Clinical Trials on Ensartinib
-
Xcovery Holding Company, LLCCompletedAdvanced Solid Tumors | Non-small Cell Lung CancerUnited States
-
Xcovery Holding Company, LLCActive, not recruitingNon-small Cell Lung CancerSpain, United States, China, Korea, Republic of, Canada, Hong Kong, United Kingdom, Turkey, Belgium, France, Poland, Israel, Australia, Argentina, Brazil, Czechia, Germany, Italy, Netherlands, Peru, Russian Federation
-
Xcovery Holdings, Inc.CompletedBioequivalencyUnited States
-
Fudan UniversityBetta Pharmaceuticals Co., Ltd.UnknownNonsmall Cell Lung Cancer | Brain Metastases
-
Betta Pharmaceuticals Co., Ltd.Completed
-
Betta Pharmaceuticals Co., Ltd.Fudan UniversityUnknownBrain Metastases | Lung Cancer, Nonsmall CellChina
-
Betta Pharmaceuticals Co., Ltd.CompletedNon-Small Cell Lung CancerChina
-
Janssen Research & Development, LLCCompletedDepressive Disorder | AnxietyUkraine, United Kingdom, Spain, United States, Russian Federation, Moldova, Republic of
-
Peking University Cancer Hospital & InstituteRecruitingNon Small Cell Lung CancerChina
-
Betta Pharmaceuticals Co., Ltd.CompletedSolid Tumor | Non-Small Cell Lung Cancer MetastaticChina